Impact of bronchoscopic lung volume reduction with endobronchial valves on dynamic hyperinflation: Results from the PIERCE study.
bronchoscopic lung volume reduction
dynamic hyperinflation
emphysema
endobronchial valves
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
23
05
2022
accepted:
22
02
2023
medline:
18
5
2023
pubmed:
9
3
2023
entrez:
8
3
2023
Statut:
ppublish
Résumé
Dynamic hyperinflation (DH) is a major marker of exertional dyspnoea in severe emphysema. We hypothesized that bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBVs) decreases DH. In this prospective bi-centre study from both Toulouse and Limoges Hospitals, we assessed DH during an incremental cycle ergometry before and 3 months after EBVs treatment. The primary objective was to observe the change in inspiratory capacity (IC) at isotime. Target lobe volume reduction (TLVR) and changes in residual volume (RV), forced expiratory volume in one-second (FEV Thirty-nine patients were included, of whom thirty-eight presented DH. IC and EELV at isotime significantly improved (+214 mL, p = 0.004; -713 mL, p ˂ 0.001, respectively). Mean changes were +177 mL for FEV DH decreases after EBVs treatment, and this improvement is correlated with static changes.
Sections du résumé
BACKGROUND AND OBJECTIVE
Dynamic hyperinflation (DH) is a major marker of exertional dyspnoea in severe emphysema. We hypothesized that bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBVs) decreases DH.
METHODS
In this prospective bi-centre study from both Toulouse and Limoges Hospitals, we assessed DH during an incremental cycle ergometry before and 3 months after EBVs treatment. The primary objective was to observe the change in inspiratory capacity (IC) at isotime. Target lobe volume reduction (TLVR) and changes in residual volume (RV), forced expiratory volume in one-second (FEV
RESULTS
Thirty-nine patients were included, of whom thirty-eight presented DH. IC and EELV at isotime significantly improved (+214 mL, p = 0.004; -713 mL, p ˂ 0.001, respectively). Mean changes were +177 mL for FEV
CONCLUSIONS
DH decreases after EBVs treatment, and this improvement is correlated with static changes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-532Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 Asian Pacific Society of Respirology.
Références
Davey C, Zoumot Z, Jordan S, McNulty WH, Carr DH, Hind MD, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet. 2015;386:1066-73.
Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198:1151-64.
Valipour A, Slebos DJ, Herth F, Darwiche K, Wagner M, Ficker JH, et al. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT Study. Am J Respir Crit Care Med. 2016;194:1073-82.
Klooster K, ten Hacken NHT, Hartman JE, Kerstjens HAM, van Rikxoort EM, Slebos DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med. 2015;373:2325-35.
Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017;196:1535-43.
Labarca G, Uribe JP, Pacheco C, Folch E, Kheir F, Majid A, et al. Bronchoscopic lung volume reduction with endobronchial Zephyr valves for severe emphysema: a systematic review and meta-analysis. Respiration. 2019;98:268-78.
O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3:219-32.
Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47:429-60.
Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med. 2005;171:453-60.
van Dijk M, Klooster K, Hartman JE, Ten Hacken NHT, Slebos D-J. Change in dynamic hyperinflation after bronchoscopic lung volume reduction in patients with emphysema. Lung. 2020;198:795-801.
Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med. 1997;155:1984-90.
Stubbing DG, Pengelly LD, Morse JL, Jones NL. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J Appl Physiol Respir Environ Exerc Physiol. 1980;49:511-5.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948-68.
Hartman JE, ten Hacken NHT, Klooster K, Boezen HM, de Greef MHG, Slebos DJ. The minimal important difference for residual volume in patients with severe emphysema. Eur Respir J. 2012;40:1137-41.
Egenod T, Tricard J, Fumat R, Simonneau Y, Favard F, Guillot MS, et al. Two-stage Bronchoscopic endobronchial valve treatment can Lead to progressive lung volume reduction and may decrease pneumothorax risk. Int J Chron Obstruct Pulmon Dis. 2021;16:1957-65.
O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4:225-36.
O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-40.
Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59:471-6.
Puente-Maestu L, Abad YM, Pedraza F, Sánchez G, Stringer WW. A controlled trial of the effects of leg training on breathing pattern and dynamic hyperinflation in severe COPD. Lung. 2006;184:159-67.
Dolmage TE, Goldstein RS. Repeatability of inspiratory capacity during incremental exercise in patients with severe COPD. Chest. 2002;121:708-14.
Guenette JA, Chin RC, Cory JM, Webb KA, O'Donnell DE. Inspiratory capacity during exercise: measurement, analysis, and interpretation. Pulm Med. 2013;2013:956081.
Dolmage TE, Evans RA, Goldstein RS. Defining hyperinflation as ‘dynamic’: moving toward the slope. Respir Med. 2013;107:953-8.
O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770-7.